Medigene AG

Medigene AG Announces Lead Selection for MDG2021,Expanding TCR-T KRAS Library Targeting Solid Tumours

20 June 2024,  Planegg/Martinsried, Germany- Medigene AG (Medigene, the “company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumours, announces today that it has selected its lead candidate for MDG2021, a T cell receptor engineered T cell (TCR-T) therapy targeting Kirsten rat sarcoma...